Investor Relations

We are driven to develop game changing molecular diagnostic tests for patients while creating value for shareholders. Our core value proposition is to reinvent how rapid molecular diagnostic capabilities are applied to various applications and are available to underserved communities, which is critical to saving lives.

Our GeneSpark DX molecular diagnostic platform is flexible and versatile which allows us to process different types of samples from bodily fluids to swabs. Our goal is to bring testing outside of the traditional laboratory environment and become a widely adopted point-of-care testing that enables better patient outcomes.

For more information about our progress, please check our News page

For more information about our progress,

please check our News page